{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:02:56Z","timestamp":1790812976742,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2006,7,15]],"date-time":"2006-07-15T00:00:00Z","timestamp":1152921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00432-006-0133-5","type":"journal-article","created":{"date-parts":[[2006,7,14]],"date-time":"2006-07-14T08:57:01Z","timestamp":1152867421000},"page":"17-26","source":"Crossref","is-referenced-by-count":46,"title":["Antiandrogen treatments in locally advanced prostate cancer: are they all the same?"],"prefix":"10.1007","volume":"132","author":[{"given":"David","family":"Gillatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,7,15]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1517\/14656566.6.7.1095","volume":"6","author":"KB Adelson","year":"2005","unstructured":"Adelson KB, Loprinzi CL, Hershman DL (2005) Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother 6:1095\u20131106","journal-title":"Expert Opin Pharmacother"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1464-410X.2003.04026.x","volume":"91","author":"J Anderson","year":"2003","unstructured":"Anderson J (2003) The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 91:455\u2013461","journal-title":"BJU Int"},{"key":"133_CR3","unstructured":"Aus G, Abbou CC, Bolla M, Heidenreich A, Van Poppel H, Schmid H-P, Wolff JM, Zattoni F (2005) European Association of Urology guidelines on prostate cancer. http:\/\/www.uroweb.nl\/files\/uploaded_files\/2005Prostate%20Cancer.pdf (accessed 19 December 2005)"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00002512-199405010-00006","volume":"5","author":"LB Barradell","year":"1994","unstructured":"Barradell LB, Faulds D (1994) Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 5:59\u201380","journal-title":"Drugs Aging"},{"key":"133_CR5","doi-asserted-by":"crossref","unstructured":"Berruti A, Dogliotti L, Terrone C, Cerruti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A, Gruppo Onco Urologico Piemontese (GOUP) ROP (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation. J Urol 167:2361\u20132367","DOI":"10.1016\/S0022-5347(05)64985-3"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa043739","volume":"352","author":"A Bill-Axelson","year":"2005","unstructured":"Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson JE (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977\u20131984","journal-title":"N Engl J Med"},{"key":"133_CR7","doi-asserted-by":"crossref","unstructured":"Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G, for the Italian Prostate Cancer Project (1999) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 17:2027\u20132038","DOI":"10.1200\/JCO.1999.17.7.2027"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23:808\u2013815","journal-title":"J Clin Oncol"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000480795","volume":"32","author":"L Boccon-Gibod","year":"1997","unstructured":"Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Esctein Fraysse C (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32:391\u2013396","journal-title":"Eur Urol"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103\u2013108","journal-title":"Lancet"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdi098","volume":"16","author":"P Boyle","year":"2005","unstructured":"Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481\u2013488","journal-title":"Ann Oncol"},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.1996.14.8.2250","volume":"14","author":"A Chang","year":"1996","unstructured":"Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D (1996) Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14:2250\u20132257","journal-title":"J Clin Oncol"},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1569-9056(04)90222-9","volume":"3","author":"G Conti","year":"2004","unstructured":"Conti G, Cretarola E, Boccardo F, Battaglia M, Di Tonno P, De Antoni P, Zattoni F, Galassi P, Durand F (2004) Tamoxifen is safe and effective in preventing gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficacy (abs 221). Eur Urol Suppl 3:58","journal-title":"Eur Urol Suppl"},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181\u2013186","journal-title":"J Urol"},{"key":"133_CR15","doi-asserted-by":"crossref","unstructured":"Debruyne FJM, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P, for the Liarozole Study Group (1998) Liarozole\u2014a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology 52:72\u201381","DOI":"10.1016\/S0090-4295(98)00129-0"},{"key":"133_CR16","doi-asserted-by":"crossref","unstructured":"Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L, for the Italian Prostatic Cancer Project (1991) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 146:377\u2013381","DOI":"10.1016\/S0022-5347(17)37799-6"},{"key":"133_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/106002809703100112","volume":"31","author":"EJ Dole","year":"1997","unstructured":"Dole EJ, Holdsworth MT (1997) Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 31:65\u201375","journal-title":"Ann Pharmacother"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1561095042000191655","volume":"4","author":"R-O Fourcade","year":"2004","unstructured":"Fourcade R-O, McLeod D (2004) Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology 4:5\u201313","journal-title":"UroOncology"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1464-410X.1993.tb16074.x","volume":"71","author":"DA Gillatt","year":"1993","unstructured":"Gillatt DA, Bolton CH, Chadwick D, Downs LG, Hopton MI, Gingell JC (1993) Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol 71:728\u2013730","journal-title":"Br J Urol"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","volume":"61","author":"CS Higano","year":"2003","unstructured":"Higano CS (2003) Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61:32\u201338","journal-title":"Urology"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","volume":"167","author":"GW Hull","year":"2002","unstructured":"Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528\u2013534","journal-title":"J Urol"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)55844-9","volume":"123","author":"K Isurugi","year":"1980","unstructured":"Isurugi K, Fukutani K, Ishida H, Hosoi Y (1980) Endocrine effects of cyproterone acetate in patients with prostatic cancer. J Urol 123:180\u2013183","journal-title":"J Urol"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1464-410x.2001.00988.x","volume":"87","author":"P Iversen","year":"2001","unstructured":"Iversen P, Melezinek I, Schmidt A (2001) Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 87:47\u201356","journal-title":"BJU Int"},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","volume":"164","author":"P Iversen","year":"2000","unstructured":"Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3\u00a0years of followup. J Urol 164:1579\u20131582","journal-title":"J Urol"},{"key":"133_CR25","doi-asserted-by":"crossref","unstructured":"Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K, Scandinavian Prostatic Cancer Group (SPCG) (2002) A randomised comparison of bicalutamide (\u2018Casodex\u2019) 150\u00a0mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. Eur Urol 42:204\u2013211","DOI":"10.1016\/S0302-2838(02)00311-1"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1464-410X.1980.tb02961.x","volume":"52","author":"GH Jacobi","year":"1980","unstructured":"Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol 52:208\u2013215","journal-title":"Br J Urol"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"key":"133_CR28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0090-4295(98)00428-2","volume":"52","author":"R Kirby","year":"1998","unstructured":"Kirby R (1998) Treatment options for early prostate cancer. Urology 52:948\u2013962","journal-title":"Urology"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1464-410X.1988.tb05062.x","volume":"61","author":"F Lund","year":"1988","unstructured":"Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 61:140\u2013142","journal-title":"Br J Urol"},{"key":"133_CR30","doi-asserted-by":"crossref","unstructured":"McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, on behalf of the \u2018Casodex\u2019 Early Prostate Cancer Trialists\u2019 Group (2006) Bicalutamide 150\u00a0mg plus standard care versus standard care alone for early prostate cancer. BJU Int 97:247\u2013254","DOI":"10.1111\/j.1464-410X.2005.06051.x"},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","volume":"341","author":"EM Messing","year":"1999","unstructured":"Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781\u20131788","journal-title":"N Engl J Med"},{"key":"133_CR32","first-page":"396","volume":"169","author":"E Messing","year":"2003","unstructured":"Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED (2003) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10\u00a0years of EST 3886 (abs 1480). J Urol 169:396","journal-title":"J Urol"},{"key":"133_CR33","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1679::AID-CNCR24>3.0.CO;2-Y","volume":"83","author":"CJ Mettlin","year":"1998","unstructured":"Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR (1998) The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83:1679\u20131684","journal-title":"Cancer"},{"key":"133_CR34","first-page":"293","volume":"71","author":"R Migliari","year":"1999","unstructured":"Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M (1999) Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 71:293\u2013302","journal-title":"Arch Ital Urol Androl"},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","volume":"11","author":"T Nishiyama","year":"2004","unstructured":"Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K (2004) Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 11:735\u2013741","journal-title":"Int J Urol"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/014107688607900407","volume":"79","author":"RB Paisey","year":"1986","unstructured":"Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC (1986) Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 79:210\u2013211","journal-title":"J R Soc Med"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, Krish RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate\u2014long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285\u20131290","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"133_CR38","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"133_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.pcan.4500782","volume":"8","author":"D Saltzstein","year":"2005","unstructured":"Saltzstein D, Sieber P, Morris T, Gallo J (2005) Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 8:75\u201383","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"133_CR40","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der FH, Collette L, De Reijke TM, Whelan P, members of the EORTC Genitourinary Group (2000) Prostate cancer treated by anti-androgens: is sexual function preserved? Br J Cancer 82:283\u2013290","DOI":"10.1054\/bjoc.1999.0916"},{"key":"133_CR41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eururo.2003.11.016","volume":"45","author":"FH Schr\u00f6der","year":"2004","unstructured":"Schr\u00f6der FH, Whelan P, De Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L (2004) Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the \u201cEuropean Organization for Research and Treatment of Cancer\u201d (EORTC) Protocol 30892. Eur Urol 45:457\u2013464","journal-title":"Eur Urol"},{"key":"133_CR42","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.281.17.1598","volume":"281","author":"WU Shipley","year":"1999","unstructured":"Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD (1999) Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis. JAMA 281:1598\u20131604","journal-title":"JAMA"},{"key":"133_CR43","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","volume":"171","author":"PR Sieber","year":"2004","unstructured":"Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (2004) Bicalutamide 150\u00a0mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171:2272\u20132276","journal-title":"J Urol"},{"key":"133_CR44","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22:2546\u20132553","journal-title":"J Clin Oncol"},{"key":"133_CR45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000473717","volume":"29","author":"SC Thorpe","year":"1996","unstructured":"Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O\u2019Boyle PJ (1996) A prospective, randomised study to compare goserelin acetate (Zoladex\u00ae) versus cyproterone acetate (Cyprostat\u00ae) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29:47\u201354","journal-title":"Eur Urol"},{"key":"133_CR46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","volume":"60","author":"CJ Tyrrell","year":"2004","unstructured":"Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10\u00a0Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 60:476\u2013483","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"133_CR47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.eururo.2004.12.003","volume":"47","author":"H Poppel Van","year":"2005","unstructured":"Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L (2005) Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 47:587\u2013592","journal-title":"Eur Urol"},{"key":"133_CR48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","volume":"41","author":"J Verhelst","year":"1994","unstructured":"Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, Mattelaer J, D\u2019Hulster D, Mahler Ch (1994) Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 41:525\u2013530","journal-title":"Clin Endocrinol (Oxf)"},{"key":"133_CR49","doi-asserted-by":"crossref","unstructured":"de Voogt HJ, Smith PH, Pavone-Macaluso M, De Pauw M, Suciu S, members of the European Organization for Research on Treatment of Cancer Urological Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135:303\u2013307","DOI":"10.1016\/S0022-5347(17)45620-5"},{"key":"133_CR50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2003.10.013","volume":"45","author":"MP Wirth","year":"2004a","unstructured":"Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M (2004a) Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45:267\u2013270","journal-title":"Eur Urol"},{"key":"133_CR51","doi-asserted-by":"crossref","unstructured":"Wirth MP, See WA, McLeod D, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists\u2019 Group (2004b) Bicalutamide 150\u00a0mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4\u00a0years. J Urol 172:1865\u20131870","DOI":"10.1097\/01.ju.0000140159.94703.80"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-006-0133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-006-0133-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-006-0133-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T16:39:45Z","timestamp":1587055185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-006-0133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,15]]},"references-count":51,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s00432-006-0133-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,15]]}}}